Lexaria Bioscience (LEXX) POS AM 12 Feb 21 Prospectus update (post-effective amendment) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Aug. 31, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	Lexaria Bioscience Corp.
Entity Central Index Key	0001348362
Entity Filer Category	Non-accelerated Filer
Document Type	POS AM
Amendment Flag	true
Amendment Description	This Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333- 238915) (the “Registration Statement”) of Lexaria Bioscience Corp. (the “Company”) is being filed pursuant to the undertakings in Item 17 of the Registration Statement to update and supplement the information contained in the Registration Statement as originally declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on June 11, 2020, to (i) include the information contained in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2020 that was filed with the SEC on October 15, 2020 and (ii) to update certain other information in the Registration Statement. This Post-Effective Amendment No. 1 is also being filed to deregister 247,559 shares of the Company’s common stock that have been sold under the Registration Statement 22,570 shares of common stock underlying expired warrants and 2,000 shares of common stock underlying warrants due to failure to provide confirmation of ownership. For this reason, this Post-Effective Amendment No. 1 only includes 483,568 shares of the Company’s common stock registered under the Registration Statement.   All share and per share information in this Post-Effective Amendment No. 1 has been adjusted to reflect a one-for-thirty reverse stock split of the Company’s common stock, which was effective at 4:30 P.M Eastern time on January 11, 2021. No additional securities are being registered under this Post-Effective Amendment No. 1. All applicable registration fees were paid at the time of the original filing of the Registration Statement.
Entity Small Business	true
Entity Emerging Growth Company	false

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Current
Cash and cash equivalents	$ 1,293,749	$ 1,285,147
Marketable securities (Note 19)	19,321	64,214
Accounts receivable (Note 7)	313,925	273,145
Inventory (Note 8)	116,871	127,396
Prepaid expenses and deposit (Note 18)	182,095	68,927
Total Current Assets	1,925,961	1,818,829
Non-current assets, net
Lease right of use	126,920	0
Intellectual Property (Note 9)	292,000	265,127
Property & equipment (Note 10)	483,357	591,263
Total Non-current Assets	902,277	856,390
TOTAL ASSETS	2,828,238	2,675,219
Current
Accounts payable and accrued liabilities (Note 11)	86,920	136,411
Deferred revenue (Note 14)	44,255
Due to related party (Note 15)	58,704	48,096
Lease current (Note 17)	36,038	0
Total Current Liabilities	225,917	184,507
Long Term
Lease long term(Note 17)	89,393
Loan payable	30,670
Total Long Term Liabilities	120,063
TOTAL LIABILITIES	345,980	184,507
STOCKHOLDERS' EQUITY
Share capital (Note 12) Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Issued and outstanding:90,044,312 common shares at August 31, 2020 and 78,787,134 common shares at August 31, 2019	90,044	78,787
Additional paid-in capital (Note 12, 13)	30,237,355	26,172,453
Deficit	(27,802,198)	(23,868,202)
Equity attributable to shareholders of the Company	2,525,201	2,383,038
Non-Controlling Interest	(42,943)	107,674
Total Stockholders' Equity	2,482,258	2,490,712
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,828,238	$ 2,675,219

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares	Aug. 31, 2020	Aug. 31, 2019
Statement of Financial Position [Abstract]
Common stock, shares authorized	220,000,000	220,000,000
Common stock, par value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares, issued	90,044,312	78,787,134
Common stock, shares, outstanding	90,044,312	78,787,134

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Income Statement [Abstract]
Revenue (Note 14)	$ 384,543	$ 222,610
Cost of goods sold	99,378	22,893
Gross profit	285,165	199,717
Expenses
Accounting and audit	78,650	77,388
Depreciation and amortization (Note 8, 9, 10)	112,750	60,550
Advertising and promotions	204,277	515,360
Bad debt	50,000	75,000
Consulting (Notes 13, 15, 17)	2,193,076	1,444,735
Investor relations	184,277	203,893
Legal and professional	371,844	670,863
Office and miscellaneous	292,880	297,209
Research and development	387,074	555,730
Travel	47,336	100,587
Wages & salaries	401,283	333,199
Realized loss on disposal of marketable securities (Note 19)	18,198
Unrealized Loss on marketable securities (Note 19)	19,893	16,434
Inventory writeoff (Note 8)	8,240	7,182
Total Operating Expenses	4,369,778	4,358,130
Net (loss) and comprehensive loss for the year	(4,084,613)	(4,158,413)
Net (loss) and comprehensive loss attributable to:
Common shareholders	(3,933,996)	(4,099,420)
Non-controlling interest	$ (150,617)	$ (58,993)
Basic and diluted (loss) per share (in dollars per share)	$ (0.05)	$ (0.05)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	83,201,271	77,792,263

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Cash flows used in operating activities
Net loss and comprehensive loss	$ (4,084,613)	$ (4,158,413)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	1,139,270	626,692
Depreciation and amortization (Note 8, 9, 10)	112,750	60,550
Inventory writeoff (Note 8)	8,240	7,182
Bad debt expense	50,000	75,000
Noncash right of use lease expense	(34,831)
Realized loss on disposal of marketable securities (Note 19)	18,198
Unrealized loss on marketable securities (Note 19)	19,893	16,434
Common shares issued for services	100,000	234,500
Warrants issued for services	168,833	52,817
Change in working capital
Accounts receivable	(90,780)	(138,644)
Inventory	4,213	(47,345)
Prepaid expenses and deposits	(113,168)	124,805
Accounts payable and accrued liabilities	(49,491)	100,626
Due to related parties	10,608	40,241
Operating lease liability	33,342
Deferred revenue	44,255
Net cash used in operating activities	(2,663,281)	(3,005,555)
Cash flows used in investing activities
Sale of marketable securities (Note 20)	6,802
Intellectual Property	(33,645)	(122,982)
Property & equipment	0	(646,183)
Net cash used in investing activities	(26,843)	(769,165)
Cash flows from financing activities
Investment from NCI		1,000,000
Long Term Loan	30,670
Proceeds from issuance of equity	2,668,056	2,332,683
Net cash from financing activities	2,698,726	3,332,683
Decrease in cash and cash equivalents	8,602	(442,037)
Cash and cash equivalents, beginning of year	1,285,147	1,727,184
Cash and cash equivalents, end of year	1,293,749	1,285,147
Supplemental information of cash flows:
Income taxes paid in cash	$ (12,978)	13,919
Reclassification of NCI to additional paid in capital on acquisition		$ 833,333

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	DEFICIT	NCI	AOCI	Total
Balance at Aug. 31, 2018	$ 75,533	$ 22,095,682	$ (19,768,782)		$ (14,247)	$ 2,388,186
Balance (Shares) at Aug. 31, 2018	75,533,471
Shares issued for services	$ 250	234,250				$ 234,500	[1]
Shares issued for services (Shares)	250,000					250,000	[1]
Stock based compensation		626,692				$ 626,692
Private Placement	$ 947	1,469,363				1,470,310
Private Placement (Shares)	947,150
Warrants issued for services		52,817				52,817
Exercise of stock options	$ 430	65,820				$ 66,250
Exercise of stock options (in shares)	430,000					430,000
Exercise of warrants	$ 1,627	794,496				$ 796,123
Exercise of warrants (in shares)	1,626,513
Net loss			(4,099,420)			(4,099,420)
Net loss non-controlling interest						(58,993)
Non-controlling Interest				$ (58,993)		(58,993)
Other comprehensive income (loss)					14,247	14,247
Subsidiary Investment		833,333		166,667		1,000,000
Balance at Aug. 31, 2019	$ 78,787	26,172,453	(23,868,202)	107,674	0	2,490,712
Balance (Shares) at Aug. 31, 2019	78,787,134
Shares issued for services	$ 347	99,653				$ 100,000	[1]
Shares issued for services (Shares)	347,222					347,222	[1]
Stock based compensation		1,139,270				$ 1,139,270
Private Placement	$ 10,690	2,627,336				2,638,026
Private Placement (Shares)	10,689,956
Warrants issued for services		168,833				168,833
Exercise of stock options	$ 220	29,810				$ 30,030
Exercise of stock options (in shares)	220,000					220,000
Net loss			(3,933,996)		0	$ (3,933,996)
Net loss non-controlling interest						(150,617)
Non-controlling Interest				(150,617)		(150,617)
Balance at Aug. 31, 2020	$ 90,044	$ 30,237,355	$ (27,802,198)	$ (42,943)	$ 0	$ 2,482,258
Balance (Shares) at Aug. 31, 2020	90,044,312
[1]	The Company awarded the restricted common shares as required by consulting contracts.

Organization, Business and Goin

Organization, Business and Going Concern	12 Months Ended
	Aug. 31, 2020
Organization, Business And Going Concern [Abstract]
Organization, Business and Going Concern	1. Organization, Business and Going Concern Lexaria Bioscience Corp. (“Lexaria”, or the “Company”) was formed on December 9, 2004 under the laws of the State of Nevada. In March of 2014, the Company began its entry into the bioscience and alternative health and wellness business. In May 2016, the Company commenced out-licensing its patented DehydraTECH™ technology (“DehydraTECH”) for improved delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company has its office in Kelowna, BC, Canada. The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (US GAAP) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The recurring losses from operations and net capital deficiency raise substantial doubt about the Company’s ability to continue as a going concern. The Company requires additional funds to maintain its operations and developments. Management’s plans in this regard are to raise equity and debt financing as required, but there is no certainty that such financing will be available or that it will be available at acceptable terms. The outcome of these matters cannot be predicted at this time. In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak and any related adverse public health developments may adversely affect workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations at this time.

Business Risk and Liquidity

Business Risk and Liquidity	12 Months Ended
	Aug. 31, 2020
Business Risk And Liquidity [Abstract]
Business Risk and Liquidity	2. Business Risk and Liquidity The Company is subject to several categories of risk associated with its operating activities. Although we intend to develop our businesses in accordance with best ethical practices, we may suffer negative publicity if we, our partners, contractors, or customers are found to have engaged in any environmentally insensitive practices or other business practices that are viewed as unethical. Our operations may require licenses and permits from various governmental authorities. We believe that we will be able to obtain all necessary licenses and permits under applicable laws and regulations for our operations and believe we will be able to comply in all material respects with the terms of such licenses and permits. However, such licenses and permits are subject to change in various circumstances. There can be no guarantee that we will be able to obtain or maintain all necessary licenses and permits and failing to obtain or retain required licenses could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the cultivation, processing, distribution, or utilization of cannabis or cannabis derived components. Lexaria does have an ancillary involvement risk via out-licensing of its patented technology to licensees that choose to utilize DehydraTECH to manufacture products that contain locally or state approved but federally regulated and controlled contents. There can be no guarantee that changes in the regulatory framework and environment will not occur and such changes could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the production or sale of any products containing nicotine. Products containing nicotine have historically been involved in litigation in the USA. Lexaria’s corporate licensee may introduce products containing nicotine that utilize DehydraTECH to the US consumer market, which could therefore introduce third-party risks to Lexaria. Lexaria and its subsidiaries are not involved directly or indirectly in the production or sale of any pharmaceutical or anti-viral products. Licensees may enhance their product’s delivery using our Technology, which could therefore introduce third-party risks to Lexaria.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Aug. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies a) Accounting Principles These consolidated financial statements have been prepared in conformity with generally accepted accounting principles of the United States of America. All amounts, unless otherwise stated, are in United States dollars. b) Revenue Recognition Product Revenue Revenue from the sale of products is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and collectability is reasonably assured, which typically occurs upon shipment. The Company reports its sales net of the amount of actual sales returns. Sales tax collected from customers is excluded from net sales. Licensing Revenue from Intellectual Property We recognize revenue for license fees at a point in time following the transfer of our intellectual property, namely our patented lipid nutrient infusion technology DehydraTECH for infusing Active Pharmaceutical Ingredients (“API”), to the licensee, which typically occurs on delivery of documentation. Usage Fees from Intellectual Property We recognize revenue for usage fees when usage of our DehydraTECH intellectual property occurs by licensees infusing an API into one or more of their product lines for sale. c) Inventory and Cost of Sales The Company’s inventory consists of finished goods, work in progress, and raw materials. In all classes, inventory is valued at the lower of cost or market. Cost is determined on a first-in, first-out basis. Cost of sales includes all expenditures incurred in bringing the goods to the point of sale. Inventory costs and costs of sales include direct costs of the raw material, inbound freight charges, warehousing costs, handling costs (receiving and purchasing), utilities and overhead expenses. d) Cash and Cash Equivalents Cash equivalents comprise certain highly liquid instruments with a maturity of three months or less when purchased. As of August 31, 2020, and August 31, 2019, the Company held cash only. e) Equipment Equipment is stated at cost less accumulated depreciation and impairment, and depreciated using the straight-line method over their useful lives or by units of production. f) Patents Capitalized patent costs represent legal costs incurred to establish patents. When patents reach a mature stage, any associated legal costs are comprised mostly of maintenance fees and are expensed as incurred. Capitalized patent costs are amortized on a straight-line basis over the remaining life of the patent. The Company was granted its first patent on October 25, 2016, with a legal life of 20 years from the patent application’s filing date g) Stock-Based Compensation The Company accounts for its stock-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized as expenses in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. Stock-based payments issued to non-employees are recorded at their fair values and are periodically revalued as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted the Company recognizes stock-based compensation expense on vesting. h) Loss Per Share The Company applies the guidance in ASC 260 Earnings Per Share. Loss per share is computed using the weighted average number of shares outstanding during the year. Diluted loss per share is equivalent to basic loss per share because the potential exercise of the equity-based financial instruments was anti-dilutive. i) Foreign Currency Translation The Company’s operations are located in the United States of America and Canada, and it has offices in Canada. The Company maintains its accounting records in U.S. Dollars, as follows: At the transaction date, each asset, liability, revenue and expense that was acquired or incurred in a foreign currency is translated into U.S. dollars by using the exchange rate in effect at that date. At the year end, monetary assets and liabilities are translated at the exchange rate in effect at that date. The resulting foreign exchange gains and losses are included in profit or loss. j) Financial Instruments ASC 820 Fair Value Measurements and Disclosures, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and Level 3 - Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. The Company’s financial instruments consist primarily of cash, marketable securities, accounts receivable, accounts payable and accrued liabilities, and due to related parties. The carrying amounts of cash, accounts and other receivable, accounts payable and accrued liabilities, and due to related parties approximate their fair values due to their short maturities or quoted market prices. The Company is located in Canada, which results in exposure to market risks from changes in foreign currency rates. The foreign currency exchange risk is the financial risk to the Company’s operations that arise from fluctuations in foreign exchange rates and the degree of volatility of these rates. Currently, the Company does not use derivative instruments to reduce its exposure to foreign currency risk as the Company does not hold a significant position in foreign currencies, such as the Canadian dollar, and the impact of a change in a few basis points for USD/CAD is not expected to be material. k) Income Taxes The Company applies the guidance in ASC 740, Income Taxes, which requires the Company to recognize deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns using the liability method. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the year in which the differences are expected to reverse. l) Impairment of Long-Lived Assets Long-lived assets, including equipment, and intangible assets, such as the Company’s patents, are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss is recognized when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to the profit or loss. Intangible assets with indefinite lives are tested for impairment annually and in interim periods if certain events occur indicating that the carrying value of the intangible assets may be impaired. m) Comprehensive Income The Company applies ASC 220, Comprehensive Income, which establishes standards for reporting and presentation of comprehensive income, its components and accumulated balances. The Company discloses this information on its Statement of Stockholders’ Equity. Comprehensive income comprises equity changes except those transactions resulting from investments by owners and distributions to owners. n) Credit Risk and Receivable Concentration The Company places its cash with a high credit quality financial institution. As of August 31, 2020, the Company had approximately $1,293,749 in the bank (August 31, 2019: $1,285,147). As at August 31, 2020 we had $143,500 (2019 – $106,000) in IP Territory license fees receivable (Note 7) consisting of amounts due from three licensees (2019 – three). These receivable amounts are based on contractual terms for payments that are payable within twelve months of signing the definitive agreements or routine IP usage fees. To date these licensees have performed all of their required obligations. The Company incurred $50,000 in bad debt in fiscal 2020 (2019 – $75,000). As at August 31, 2020, the Company had $87,933 (2019 - $161,418) in sales tax receivable (Note 7). The Company considers its credit risk to be low for such receivables. o) Commitments and Contingencies In accordance with ASC 450-20, Accounting for Contingencies, the Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In the event that estimates or assumptions prove to differ from actual results, adjustments are made in subsequent periods to reflect more current information. Historically, the Company has not experienced any material claims. p) Research and Development Research and development costs are expensed as incurred. q) Leases On September 1, 2019, we adopted ASC Topic 842, Leases (“ASC 842”) using the optional transition method and applied the standard only to leases that existed at that date. Under the optional transition method, we do not need to restate the comparative periods in transition and will continue to present financial information and disclosures for periods before September 1, 2019, in accordance with ASC Topic 840. We have elected the package of practical expedients allowed under ASC Topic 842, which permits us to account for our existing operating leases as operating leases under the new guidance, without reassessing our prior conclusions about lease identification, lease classification and initial direct cost. As a result of the adoption of the new lease accounting guidance, we recognized on September 1, 2019, operating lease right-of-use assets of $160,289 and operating lease liabilities of $158,773. We determined the initial classification and measurement of our right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that we are reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, we use our incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that we would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. Rent expense for operating leases is recognized on a straight-line basis, unless the right-of-use asset has been impaired, over the reasonably certain lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss. For operating leases that reflect impairment, we will recognize the amortization of the right-of-use asset on a straight-lined basis over the remaining lease term with rent expense still included in operating expenses in the consolidated statements of operations and comprehensive loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date. We have elected the practical expedient to not separate lease and non-lease components. Our non-lease components are primarily related to property taxes and maintenance, which vary based on future outcomes, and thus differences to original estimates are recognized in rent expense when incurred.

Basis of Consolidation

Basis of Consolidation	12 Months Ended
	Aug. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Consolidation	4. Basis of Consolidation These consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries; Lexaria CanPharm ULC, PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp. and Lexaria Pharmaceutical Corp., and our 83.333% subsidiary Lexaria Nicotine LLC (16.667% Altria Ventures Inc., an indirect wholly-owned subsidiary of Altria Group, Inc.). All significant intercompany balances and transactions have been eliminated.

Estimates and Judgments

Estimates and Judgments	12 Months Ended
	Aug. 31, 2020
Estimates And Judgments [Abstract]
Estimates and Judgments	5. Estimates and Judgments The preparation of financial statements in conformity with U.S GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting year. Some of the Company’s accounting policies require us to make subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are highly uncertain at the time the accounting estimates are made. Although we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have been used. Changes in the accounting estimates used by the Company are reasonably likely to occur from time to time, which may have a material effect on the presentation of financial condition and results of operations. The Company reviews these estimates, judgments and assumptions periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, actual results could differ from these estimates. Significant accounting estimates and assumptions are used for, but not limited to: a) The Valuation of Deferred Tax Assets Judgement is required in determining whether deferred tax assets are recognized on the balance sheet. The recognition of deferred tax assets requires management to assess the likelihood that the Company will generate taxable income in future periods to utilize the deferred tax assets. Due to the Company’s history of losses, deferred tax assets have not been recognized by Lexaria. b) Value of Stock Options and Warrants The Company provides compensation benefits to its employees, directors, officers, and consultants, through a stock option plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. Expected volatility assumptions used in the model are based on the historical volatility of the Company’s share price. The Company uses historical data to estimate the period of option exercises for use in the valuation model. The risk-free interest rate for the expected term of the option is based on the yields of government bonds. Changes in these assumptions, especially the share price volatility and the expected life determination could have a material impact on the Company’s profit and loss for the years presented. All estimates used in the model are based on historical data which may not be representative of future results.

Recent Accounting Guidance

Recent Accounting Guidance	12 Months Ended
	Aug. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Guidance	6. Recent Accounting Guidance In February 2016 FASB issued ASU No. 201602, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation, and disclosure of leases for both lessees and the lessors. The new standard requires the lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. In November 2019 FASB issued ASU No 201910 revised the effective date based on updated criteria with the effective date for fiscal years beginning after December 15, 2020. In June 2020 FASB issued ASU No 202005 further delaying the effective date for fiscal years beginning after December 15, 2021 due to the COVID-19 pandemic. The Company has adopted this standard as of August 31, 2020 (Note 17). In June 2016, the FASB issued a new standard to replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. For trade and other receivables, loans and other financial instruments, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available for sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. In November 2019 FASB issued ASU No 201910 revised the effective date based on updated criteria with the effective date for fiscal years beginning after December 15, 2022. Application of the amendments is through a cumulative effect adjustment to deficit as of the effective date. The Company is currently assessing the impact of the standard on its consolidated financial statements. In February 2018, the FASB issued ASU No. 201802, Income Statement–Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act enacted by the U.S. federal government on December 22, 2017 (the “2017 Tax Act”). Consequently, the amendments eliminate the stranded tax effects resulting from the 2017 Tax Act and will improve the usefulness of information reported to financial statement users. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company adopted the ASU on September 1, 2019 for a $NIL effect. In June 2018, the FASB issued ASU No. 201807, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting. This is a simplification that involves several aspects of accounting for nonemployee share-based payments resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted the ASU on September 1, 2019 for a $NIL effect.

Accounts and Other Receivables

Accounts and Other Receivables	12 Months Ended
	Aug. 31, 2020
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Accounts and Other Receivables	7. Accounts and Other Receivables August 31 August 31 2020 2019 $ $ Trade and deposits receivable 82,492 5,727 Territory license fee receivable 143,500 106,000 Sales tax receivable 87,933 161,418 313,925 273,145

Inventory

Inventory	12 Months Ended
	Aug. 31, 2020
Inventory Disclosure [Abstract]
Inventory	8. Inventory August 31 2020 $ August 31 2019 $ Raw materials 51,404 45,068 Work in progress 15,705 — Finished goods 49,762 82,328 116,871 127,396 During the year ended August 31, 2020, the Company wrote down $8,240 (2019 - $7,182) of inventory to reflect its net realisable value.

Intellectual Property

Intellectual Property	12 Months Ended
	Aug. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property	9. Intellectual Property The following is a list of US capitalized patents held by the Company Issued Patent # Patent Issuance Date Patent Family US 9,474,725 B1 10/25/2016 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof US 9,839,612 B2 12/12/2017 US 9,972,680 B2 05/15/2018 US 9,974,739 B2 05/22/2018 US 10,084,044 B2 09/25/2018 US 10,103,225 B2 10/16/2018 US 10,381,440 08/13/2019 US 10,374,036 08/06/2019 US 10,756,180 08/25/2020 The Company also holds non-capitalized patents outside the US. A continuity schedule for patents is presented below: August 31 August 31 2020 2019 $ $ Balance - Beginning 265,127 146,538 Addition 33,645 122,982 Amortization* (6,772 ) (4,393 ) Balance - Ending 292,000 265,127 *The patents are amortized over their legal life of 20 years from the patent application’s filing date.

Property & Equipment

Property & Equipment	12 Months Ended
	Aug. 31, 2020
Proceeds from Sale of Property, Plant, and Equipment [Abstract]
Property & Equipment	10. Property & Equipment Year Ended August 31, 2020 Cost $ Amortization $ Accumulated Amortization $ Net Balance August 31, 2020 $ Leasehold improvements 259,981 (53,268 ) (86,610 ) 173,371 Computers 63,964 (19,681 ) (31,869 ) 32,095 Furniture fixtures equipment 34,220 (7,036 ) (13,097 ) 21,123 Lab equipment 291,235 (27,921 ) (34,467 ) 256,768 649,400 (107,906 ) (166,043 ) 483,357 Net Balance Year Ended August 31, 2019 Cost Amortization Accumulated Amortization August 31, 2019 $ $ $ $ Leasehold improvements 259,981 (33,342 ) (33,342 ) 226,639 Computers 63,964 (12,187 ) (12,187 ) 51,777 Furniture fixtures equipment 34,220 (4,205 ) (6,062 ) 28,158 Lab equipment 291,235 (6,546 ) (6,546 ) 284,689 649,400 (56,281 ) (58,137 ) 591,263 During the period $1,928 of amortization was included in the cost of inventory.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Aug. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	11. Accounts Payable and Accrued Liabilities August 31 2020 $ August 31 2019 $ Accounts Payable Trades payable 45,080 31,463 Sales tax payable — 63,616 Accrued Liabilities Corporate tax payable 3,834 — Trades payable 38,006 41,332 Total 86,920 136,411

Common Shares and Warrants

Common Shares and Warrants	12 Months Ended
	Aug. 31, 2020
Equity [Abstract]
Common Shares and Warrants	12. Common Shares and Warrants Fiscal 2020 Activity During the year ended August 31, 2020, the Company closed, pursuant to two tranches, a non-brokered private placement for an aggregate total of 1,823,745 units priced at $0.45 each. Each unit consists of one common share and one share purchase warrant. Each warrant shall entitle the holder to acquire one common share of the Company for a period of two years at a price of $0.80 per Share until the first anniversary of issuance, and thereafter at a price of $1.20 until the second anniversary of issuance. The Company paid $3,938 and issued 8,750 broker warrants. The broker warrants have a term of 24 months and are each exercisable into one common share of the Company at a price of $0.80 per share until the first anniversary of issuance, and thereafter at a price of $1.20 until the second anniversary of issuance. The fair value of these broker warrants was determined to be $1,850, which were recorded as a share issuance cost within additional paid in capital for a net effect of $Nil. The Company also issued an aggregate of 8,866,211 units at $0.23, issued in two tranches for gross proceeds of $2,039,229. Each unit consists of one common share and one full warrant. The warrants are exercisable on issuance at an exercise price of $0.35 with 8,028,254 expiring May 6, 2025 and 837,957 on May 11, 2025. Pursuant to the agent agreement $151,623 and 649,123 broker warrants with an exercise price of $0.35 expiring May 6, 2025, were paid. The broker warrants were valued at $128,329 and were recorded as a share issue cost within additional paid in capital for a net effect of $Nil. A total of $65,600 in legal fees were also paid. The company granted a total of 500,000 warrants pursuant to an agreement with a consultant valued at $98,081 that were recorded as an expense within consulting. The Company recognized $168,833 in consulting expense for warrants granted to consultants as per vesting requirements. A summary of share issuance relating to exercises and private placements is presented below: Type of Issuance Number of Shares Total Value $ Option exercise 220,000 30,030 Private placement (1) 10,689,956 2,859,914 Per agreements (2) 347,222 100,000 11,257,178 2,989,944 (1) (2) Fiscal 2019 Activity During the year ended August 31, 2019 the Company closed a non-brokered private placement for 947,150 Units priced at $1.60 each. Each unit consists of one common share and one share purchase warrant. Each warrant shall entitle the holder to acquire one common share at a price of $2.25 per share for a period of 24 months. The Company also issued 28,175 broker warrants. The broker warrants have a term of 24 months and are each exercisable into one common share of the Company at a price of $2.25. The fair value of these broker warrants was determined to be $16,095, which were recorded as a share issue cost within additional paid in capital for a net effect of $Nil. The Company granted an additional 107,737 broker warrants with a value of $6,484 that were recorded as a share issue cost within additional paid in capital for a net effect of $Nil. The Company granted a total of 100,000 warrants pursuant to an agreement with a vendor valued at $52,817 that were recorded as an expense within investor relation expense. During the year ended August 31, 2019 the Company recognized $51,448 in consulting expense for warrants previously granted to a consultant upon vesting. A summary of share issuance is presented relating to option and warrant exercises, agreement requirements and debt settlement is presented below: Type of Issuance Number of Shares Total Value $ Warrant exercise (1) 1,626,513 796,122 Option exercise 430,000 66,250 Private placement 947,150 1,515,440 Per agreements (2) 250,000 234,500 3,253,663 2,612,312 (1) Includes 384,212 broker warrants exercised for gross proceeds of $191,742 (2) The Company awarded the restricted common shares as required by consulting contracts. A continuity schedule for warrants is presented below: Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2018 3,286,274 0.72 Cancelled/Expired (17,498 ) 0.59 Exercised (1,626,513 ) 0.49 Issued 1,183,062 1.99 Balance August 31, 2019 2,825,325 1.38 Cancelled/Expired (750,000 ) 1.50 Issued 12,072,829 0.42 Balance August 31, 2020 14,148,154 0.56 The fair value of share purchase warrants granted as broker warrants, compensation units, and compensatory warrants, was estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: August 31 2020 August 31 2019 Expected volatility 91%-94 % 1% - 117 % Risk-free interest rate 0.36%-2.87 % 2.31% - 2.87 % Expected life 2 - 5 years 1 day - 2 years Dividend yield 0 % 0.00 % Estimated fair value per warrant 0.28 - 0.54 $ Nil A summary of warrants outstanding as of 31, 2020 is presented below: # of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 975,325 0.17 years 2.25 100,000 0.72 years 0.96 250,000 0.73 years 1.55 750,000 1.11 years 0.14 225,000 2.18 years 0.80 1,562,995 1.20 years 0.80 269,500 1.24 years 0.80 500,000 4.54 years 0.30 8,028,254 4.68 years 0.35 1,487,080 4.70 years 0.35 14,148,154 3.59 years 0.56

Stock Options

Stock Options	12 Months Ended
	Aug. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Options	13. Stock Options The Company has established its 2014 Stock Option Plan whereby the Board may, from time to time, grant up to 2,107,500 stock options to directors, officers, employees, and consultants, and the 2019 Equity Incentive Plan whereby the Board may, from time to time, grant up to 7,838,713 stock options to directors, officers, employees, and consultants. Stock options granted must be exercised no later than five years from the date of grant or such lesser period as determined by the Board. The exercise price of an option is equal to or greater than the closing market price of the Company’s common shares on the day preceding the date of grant. The vesting terms of each grant are set by the Board. During the year ending August 31, 2020 the formerly established 2007 Equity Incentive Plan and the 2010 Stock Option Plan were cancelled. Outstanding options were cancelled and reissued under the 2019 Equity Incentive Plan. Fiscal 2020 Activity The Company granted stock options in the year ending August 31, 2020: Quantity Exercise Price $ Life (Years) 1,000,000 0.55 5 60,000 0.43 5 550,000 0.47 5 2,538,000 0.32 5 700,000 0. 0.34 5 4,848,000 (1) 0.39 5 (1) Fiscal 2019 Activity The Company granted stock options in the year ending August 31, 2019: Quantity Exercise Price $ Life (Years) 390,000 (1) 1.27 5 240,000 (1) 1.06 5 30,000 (1) 1.16 5 350,000 0.99 5 440,000 (1) 0.99 5 48,000 (1) 0.96 5 100,000 0.81 5 450,000 (1) 0.81 5 2,048,000 1.00 (1) A continuity schedule for stock options is presented below: Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2018 4,800,000 0.71 Expired/Cancelled (1,415,000 ) 0.66 Exercised (430,000 ) 0.15 Granted 2,048,000 1.00 Balance August 31, 2019 5,003,000 0.71 Expired/Cancelled (4,483,000 ) 0.98 Exercised (220,000 ) 0.14 Granted 4,848,000 0.39 Balance August 31, 2020 (Outstanding) 5,148,000 0.37 4.30 140,634 Balance August 31, 2020 (Exercisable) 4,262,000 0.34 4.29 136,853 The fair value of options granted was estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: August 31 2020 August 31 2019 Expected volatility 95%- 96 % 100%- 144 % Risk-free interest rate 0.35%- 1.66 % 1.42%- 2.89 % Expected life 5 years 5 years Dividend yield 0 % 0 % Estimated fair value per option $ 0.31-$0.54 $ 0.60 - $1.07

Revenues

Revenues	12 Months Ended
	Aug. 31, 2020
Revenues [Abstract]
Revenues	14. Revenues August 31 2020 $ August 31 2019 $ Product sales 150,993 24,282 Licensing revenue (Note 11) 232,909 198,000 Freight revenue 641 328 384,543 222,610 The Company recognized $232,909 of licensing revenue (2019 $198,000) and $150,993 of product revenues (2019 $24,282). Licensing revenue was significantly concentrated on one licensee and $121,906 of product revenues related to sales of our intermediate product for use by five customers in their products. The licensing fees consist of IP licensing fees for transfer of the DehydraTECH technology with the signing of definitive agreements and usage fees. The licensing fees include payments due upon transfer of the technology and installment payments that are receivable within 12 months (Note 7). As of August 31, 2020, we have $44,255 in deferred revenue from customers for production of intermediate products that are expected to be produced during our next fiscal quarter.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Aug. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions Management, consulting and accounting services Cash $ % Non-Cash (2) $ % Aug 31 2020 Total $ Cash $ % Non-Cash (2) $ % Aug 31 2019 Total $ C.A.B Financial Services (1) 300,802 66 153,065 34 453,867 223,280 100 — — 223,280 M&E Services Ltd. (1) 121,664 46 143,886 54 265,550 112,377 100 — — 112,377 Docherty Management Limited (1) 242,521 47 275,614 53 518,135 195,740 100 — — 195,740 Company controlled by a director — — — — — 14,932 12 112,718 88 127,650 Directors 67,146 43 88,544 57 155,690 16,138 9 172,330 91 188,468 732,133 661,109 1,393,242 562,467 285,048 847,515 (1) (2) Due to related parties: As at August 31, 2020, $58,704 (August 31, 2019 - $48,096) was payable to related parties included in due to related parties. The related party transactions are recorded at the exchange amount established and agreed to between the related parties.

Segment Information

Segment Information	12 Months Ended
	Aug. 31, 2020
Segment Reporting [Abstract]
Segment Information	16. Segment Information The Company’s operations involve the development and usage, including licensing, of DehydraTECH. Lexaria is centrally managed and its chief operating decision makers, being the President and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property Licensing and Consumer Products. Licensing revenues are significantly concentrated on three licensees. IP Licensing Consumer Products Corporate Consolidated Total External revenue 232,909 151,634 — 384,543 Cost of goods sold — (99,378 ) — (99,378 ) Operating expenses (1,601,595 ) (1,043,956 ) (1,724,227 ) (4,369,778 ) Segment loss (1,368,686 ) (991,700 ) (1,724,227 ) (4,084,613 ) Total assets 692,268 116,871 2,019,099 2,828,238 Capital Asset by Region Cost Net Balance Cost Net Balance Canada Canada Total Net Balance Balance Year Ended August 31, 2020 $ $ $ $ $ Leasehold Improvements — — 259,981 173,371 173,371 Computers — — 63,964 32,095 32,095 Furniture Fixtures Equipment 3,094 — 31,126 21,123 21,123 Lab Equipment 98,050 85,264 193,185 171,505 256,769 101,144 85,264 548,256 398,094 483,358 Capital Asset by Region Cost Net Balance Cost Net Balance Canada Canada Total Net Balance Balance Year Ended August 31, 2019 $ $ $ $ $ Leasehold Improvements — — 259,981 226,638 226,638 Computers — — 63,964 51,776 51,776 Furniture Fixtures Equipment 3,094 619 31,126 27,540 28,159 Lab Equipment 98,050 85,420 193,185 199,269 284,689 101,144 86,039 548,256 505,223 591,262

Commitments, Significant Contra

Commitments, Significant Contracts and Contingencies	12 Months Ended
	Aug. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments, Significant Contracts and Contingencies	17. Commitments, Significant Contracts and Contingencies Management and Service Agreements As at August 31, 2020, the Company is party to the following contractual commitments: Party Monthly Commitment Expiry Date C.A.B Financial Services CAD $29,706 January 1, 2022 Docherty Management Ltd. CAD $25,609 January 1, 2022 M&E Services Ltd. CAD $13,997 June 1, 2021 Corporate Development CAD $1,500 Month to Month Office Management CAD $10,800 August 15, 2022 Research & Development CAD $3,854 Month to Month Office operating lease (1) CAD $4,823 November 15, 2023 Right of Use Assets - Operating Lease (1) Corporate office and R&D lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. In addition to minimum lease payments, the lease requires us to pay property taxes and operating costs which are subject to annual adjustments. Right of use assets - operating leases: $ September 1, 2019 160,289 Amortization (33,369 ) Total lease assets 126,920 Liabilities: September 1, 2019 158,773 Lease payments (43,764 ) Interest accretion 10,423 Total lease liabilities 125,431 Operating lease cost as at August 31, 2020 $ 126,920 Operating cash flows for lease $ 43,764 Remaining lease term 3.1 Years Discount rate 7.25 % Pursuant to the terms of the Company’s lease agreements in effect at August 31, 2020, the following table summarizes the Company’s maturities of operating lease liabilities as of August 31, 2020: 2021 43,950 2022 44,599 2023 44,815 2024 7,469 Thereafter — Total lease payments 140,832 Less: imputed interest (15,401 ) Present value of operating lease liabilities 125,431 Less: current obligations under leases (36,038 ) Total 89,393

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Aug. 31, 2020
Prepaid Expense, Current [Abstract]
Prepaid Expenses	18. Prepaid Expenses Prepaid expenses consist of the following at August 31, 2020 and August 31, 2019: August 31 2020 $ August 31 2019 $ Advertising & conferences 21,878 39,143 Legal fees 47,498 — Licence, filing fees, dues 8,541 — Office & insurance 78,792 29,784 Research & development 25,386 — 182,095 68,927

Marketable Securities

Marketable Securities	12 Months Ended
	Aug. 31, 2020
Marketable Securities [Abstract]
Marketable Securities	19. Marketable Securities The components of Marketable Securities were as follows: Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2019 Common Stock 81,250 9,335 (12,124 ) Total 81,250 9,335 (26,973 ) 63,612 August Common Stock 56,250 9,997 (38,584 ) Total 56,250 9,997 (46,926 ) 19,321 We realized an $18,198 loss and received $6,802 in net proceeds on the sale of marketable securities. Unrealized losses from common stock are due to market price movements. Management does not believe any remaining unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence.

Income Tax

Income Tax	12 Months Ended
	Aug. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax	20. Income Tax The following table reconciles the income tax benefit at the U.S. Federal statutory rate to income tax benefit at the Company’s effective tax rates as at August 31, 2020 and 2019: August 31 2020 $ August 31 2019 $ Loss before taxes (3,987,018 ) (4,158,413 ) Expected income tax recovery (856,424 ) (883,841 ) Non-deductible items 200,573 8,544 Change in estimates 92,083 948 Effect of changes in foreign and long-term tax rates — — Change in valuation allowance 566,087 892,013 Total income taxes 2,319 17,664 Deferred taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Deferred tax assets at August 31, 2020 and 2019 are comprised of the following: August 31 2020 $ August 31 2019 $ Non-capital losses 5,588,526 5,022,440 Marketable securities 2,300 2,300 Total unrecognized deferred tax assets 5,590,826 5,024,740 The Company has net operating loss carry-forwards of approximately $26,891,000 which may be carried forward to apply against future year income tax for U.S. tax purposes. Year Amount Canada 2025 76,000 — 2026 508,000 — 2027 1,056,000 — 2028 720,000 — 2029 753,000 — 2030 552,000 — 2031 538,000 — 2032 252,000 — 2033 344,000 — 2034 3,257,000 — 2035 1,934,000 — 2036 1,150,000 — 2037 1,857,000 — 2038 — — 2039 — 242,000 2040 — 309,000 Indefinite 13,343,000 — 26,340,000 551,000 Total 26,891,000

Subsequent Events

Subsequent Events	12 Months Ended
	Aug. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events September 22, 2020, Lexaria announced that U.S. Patent No. 10,756,180 was granted that provides patent claims that protect the use of Lexaria's DehydraTECH technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats. The patent is entitled Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof .

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2020
Accounting Policies [Abstract]
Accounting Principles	a) Accounting Principles These consolidated financial statements have been prepared in conformity with generally accepted accounting principles of the United States of America. All amounts, unless otherwise stated, are in United States dollars.
Revenue Recognition	b) Revenue Recognition Product Revenue Revenue from the sale of products is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and collectability is reasonably assured, which typically occurs upon shipment. The Company reports its sales net of the amount of actual sales returns. Sales tax collected from customers is excluded from net sales. Licensing Revenue from Intellectual Property We recognize revenue for license fees at a point in time following the transfer of our intellectual property, namely our patented lipid nutrient infusion technology DehydraTECH for infusing Active Pharmaceutical Ingredients (“API”), to the licensee, which typically occurs on delivery of documentation. Usage Fees from Intellectual Property We recognize revenue for usage fees when usage of our DehydraTECH intellectual property occurs by licensees infusing an API into one or more of their product lines for sale.
Inventory and Cost of Sales	c) Inventory and Cost of Sales The Company’s inventory consists of finished goods, work in progress, and raw materials. In all classes, inventory is valued at the lower of cost or market. Cost is determined on a first-in, first-out basis. Cost of sales includes all expenditures incurred in bringing the goods to the point of sale. Inventory costs and costs of sales include direct costs of the raw material, inbound freight charges, warehousing costs, handling costs (receiving and purchasing), utilities and overhead expenses.
Cash and Cash Equivalents	d) Cash and Cash Equivalents Cash equivalents comprise certain highly liquid instruments with a maturity of three months or less when purchased. As of August 31, 2020, and August 31, 2019, the Company held cash only.
Equipment	e) Equipment Equipment is stated at cost less accumulated depreciation and impairment, and depreciated using the straight-line method over their useful lives or by units of production.
Patents	f) Patents Capitalized patent costs represent legal costs incurred to establish patents. When patents reach a mature stage, any associated legal costs are comprised mostly of maintenance fees and are expensed as incurred. Capitalized patent costs are amortized on a straight-line basis over the remaining life of the patent. The Company was granted its first patent on October 25, 2016, with a legal life of 20 years from the patent application’s filing date
Stock-Based Compensation	g) Stock-Based Compensation The Company accounts for its stock-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized as expenses in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. Stock-based payments issued to non-employees are recorded at their fair values and are periodically revalued as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted the Company recognizes stock-based compensation expense on vesting.
Loss Per Share	h) Loss Per Share The Company applies the guidance in ASC 260 Earnings Per Share. Loss per share is computed using the weighted average number of shares outstanding during the year. Diluted loss per share is equivalent to basic loss per share because the potential exercise of the equity-based financial instruments was anti-dilutive.
Foreign Currency Translation	i) Foreign Currency Translation The Company’s operations are located in the United States of America and Canada, and it has offices in Canada. The Company maintains its accounting records in U.S. Dollars, as follows: At the transaction date, each asset, liability, revenue and expense that was acquired or incurred in a foreign currency is translated into U.S. dollars by using the exchange rate in effect at that date. At the year end, monetary assets and liabilities are translated at the exchange rate in effect at that date. The resulting foreign exchange gains and losses are included in profit or loss.
Financial Instruments	j) Financial Instruments ASC 820 Fair Value Measurements and Disclosures, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and Level 3 - Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. The Company’s financial instruments consist primarily of cash, marketable securities, accounts receivable, accounts payable and accrued liabilities, and due to related parties. The carrying amounts of cash, accounts and other receivable, accounts payable and accrued liabilities, and due to related parties approximate their fair values due to their short maturities or quoted market prices. The Company is located in Canada, which results in exposure to market risks from changes in foreign currency rates. The foreign currency exchange risk is the financial risk to the Company’s operations that arise from fluctuations in foreign exchange rates and the degree of volatility of these rates. Currently, the Company does not use derivative instruments to reduce its exposure to foreign currency risk as the Company does not hold a significant position in foreign currencies, such as the Canadian dollar, and the impact of a change in a few basis points for USD/CAD is not expected to be material.
Income Taxes	k) Income Taxes The Company applies the guidance in ASC 740, Income Taxes, which requires the Company to recognize deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns using the liability method. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the year in which the differences are expected to reverse.
Impairment of Long-Lived Assets	l) Impairment of Long-Lived Assets Long-lived assets, including equipment, and intangible assets, such as the Company’s patents, are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss is recognized when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to the profit or loss. Intangible assets with indefinite lives are tested for impairment annually and in interim periods if certain events occur indicating that the carrying value of the intangible assets may be impaired.
Comprehensive Income	m) Comprehensive Income The Company applies ASC 220, Comprehensive Income, which establishes standards for reporting and presentation of comprehensive income, its components and accumulated balances. The Company discloses this information on its Statement of Stockholders’ Equity. Comprehensive income comprises equity changes except those transactions resulting from investments by owners and distributions to owners.
Credit Risk and Receivable Concentration	n) Credit Risk and Receivable Concentration The Company places its cash with a high credit quality financial institution. As of August 31, 2020, the Company had approximately $1,293,749 in the bank (August 31, 2019: $1,285,147). As at August 31, 2020 we had $143,500 (2019 – $106,000) in IP Territory license fees receivable (Note 7) consisting of amounts due from three licensees (2019 – three). These receivable amounts are based on contractual terms for payments that are payable within twelve months of signing the definitive agreements or routine IP usage fees. To date these licensees have performed all of their required obligations. The Company incurred $50,000 in bad debt in fiscal 2020 (2019 – $75,000). As at August 31, 2020, the Company had $87,933 (2019 - $161,418) in sales tax receivable (Note 7). The Company considers its credit risk to be low for such receivables.
Commitments and Contingencies	o) Commitments and Contingencies In accordance with ASC 450-20, Accounting for Contingencies, the Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In the event that estimates or assumptions prove to differ from actual results, adjustments are made in subsequent periods to reflect more current information. Historically, the Company has not experienced any material claims.
Research and Development	p) Research and Development Research and development costs are expensed as incurred.
Leases	q) Leases On September 1, 2019, we adopted ASC Topic 842, Leases (“ASC 842”) using the optional transition method and applied the standard only to leases that existed at that date. Under the optional transition method, we do not need to restate the comparative periods in transition and will continue to present financial information and disclosures for periods before September 1, 2019, in accordance with ASC Topic 840. We have elected the package of practical expedients allowed under ASC Topic 842, which permits us to account for our existing operating leases as operating leases under the new guidance, without reassessing our prior conclusions about lease identification, lease classification and initial direct cost. As a result of the adoption of the new lease accounting guidance, we recognized on September 1, 2019, operating lease right-of-use assets of $160,289 and operating lease liabilities of $158,773. We determined the initial classification and measurement of our right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that we are reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, we use our incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that we would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. Rent expense for operating leases is recognized on a straight-line basis, unless the right-of-use asset has been impaired, over the reasonably certain lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss. For operating leases that reflect impairment, we will recognize the amortization of the right-of-use asset on a straight-lined basis over the remaining lease term with rent expense still included in operating expenses in the consolidated statements of operations and comprehensive loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date. We have elected the practical expedient to not separate lease and non-lease components. Our non-lease components are primarily related to property taxes and maintenance, which vary based on future outcomes, and thus differences to original estimates are recognized in rent expense when incurred.

Accounts and Other Receivables

Accounts and Other Receivables (Tables)	12 Months Ended
	Aug. 31, 2020
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Schedule of accounts and other receivables	August 31 August 31 2020 2019 $ $ Trade and deposits receivable 82,492 5,727 Territory license fee receivable 143,500 106,000 Sales tax receivable 87,933 161,418 313,925 273,145

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Aug. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	August 31 2020 $ August 31 2019 $ Raw materials 51,404 45,068 Work in progress 15,705 — Finished goods 49,762 82,328 116,871 127,396

Intellectual Property (Tables)

Intellectual Property (Tables)	12 Months Ended
	Aug. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of patents	August 31 August 31 2020 2019 $ $ Balance - Beginning 265,127 146,538 Addition 33,645 122,982 Amortization* (6,772 ) (4,393 ) Balance - Ending 292,000 265,127 *The patents are amortized over their legal life of 20 years from the patent application’s filing date.

Property & Equipment (Tables)

Property & Equipment (Tables)	12 Months Ended
	Aug. 31, 2020
Proceeds from Sale of Property, Plant, and Equipment [Abstract]
Schedule of property & equipment	Year Ended August 31, 2020 Cost $ Amortization $ Accumulated Amortization $ Net Balance August 31, 2020 $ Leasehold improvements 259,981 (53,268 ) (86,610 ) 173,371 Computers 63,964 (19,681 ) (31,869 ) 32,095 Furniture fixtures equipment 34,220 (7,036 ) (13,097 ) 21,123 Lab equipment 291,235 (27,921 ) (34,467 ) 256,768 649,400 (107,906 ) (166,043 ) 483,357 Net Balance Year Ended August 31, 2019 Cost Amortization Accumulated Amortization August 31, 2019 $ $ $ $ Leasehold improvements 259,981 (33,342 ) (33,342 ) 226,639 Computers 63,964 (12,187 ) (12,187 ) 51,777 Furniture fixtures equipment 34,220 (4,205 ) (6,062 ) 28,158 Lab equipment 291,235 (6,546 ) (6,546 ) 284,689 649,400 (56,281 ) (58,137 ) 591,263

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Aug. 31, 2020
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued liabilities	August 31 2020 $ August 31 2019 $ Accounts Payable Trades payable 45,080 31,463 Sales tax payable — 63,616 Accrued Liabilities Corporate tax payable 3,834 — Trades payable 38,006 41,332 Total 86,920 136,411

Common Shares and Warrants (Tab

Common Shares and Warrants (Tables)	12 Months Ended
	Aug. 31, 2020
Equity [Abstract]
Schedule of option and warrant exercises	Type of Issuance Number of Shares Total Value $ Option exercise 220,000 30,030 Private placement (1) 10,689,956 2,859,914 Per agreements (2) 347,222 100,000 11,257,178 2,989,944 (1) (2) Type of Issuance Number of Shares Total Value $ Warrant exercise (1) 1,626,513 796,122 Option exercise 430,000 66,250 Private placement 947,150 1,515,440 Per agreements (2) 250,000 234,500 3,253,663 2,612,312 (1) Includes 384,212 broker warrants exercised for gross proceeds of $191,742 (2) The Company awarded the restricted common shares as required by consulting contracts.
Schedule of warrant	Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2018 3,286,274 0.72 Cancelled/Expired (17,498 ) 0.59 Exercised (1,626,513 ) 0.49 Issued 1,183,062 1.99 Balance August 31, 2019 2,825,325 1.38 Cancelled/Expired (750,000 ) 1.50 Issued 12,072,829 0.42 Balance August 31, 2020 14,148,154 0.56
Schedule of warrants granted as compensation warrants by using the Black-Scholes option pricing model	August 31 2020 August 31 2019 Expected volatility 91%-94 % 1% 117 % Risk-free interest rate 0.36%-2.87 % 2.31% 2.87 % Expected life 2 5 years 1 day 2 years Dividend yield 0 % 0.00 % Estimated fair value per warrant 0.28 0.54 $Nil $0.57
Schedule of warrants outstanding	# of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 975,325 0.17 years 2.25 100,000 0.72 years 0.96 250,000 0.73 years 1.55 750,000 1.11 years 0.14 225,000 2.18 years 0.80 1,562,995 1.20 years 0.80 269,500 1.24 years 0.80 500,000 4.54 years 0.30 8,028,254 4.68 years 0.35 1,487,080 4.70 years 0.35 14,148,154 3.59 years 0.56

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Aug. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of exercise price	Fiscal 2020 Activity The Company granted stock options in the year ending August 31, 2020: Quantity Exercise Price $ Life (Years) 1,000,000 0.55 5 60,000 0.43 5 550,000 0.47 5 2,538,000 0.32 5 700,000 0. 0.34 5 4,848,000 (1) 0.39 5 (1) Fiscal 2019 Activity The Company granted stock options in the year ending August 31, 2019: Quantity Exercise Price $ Life (Years) 390,000 (1) 1.27 5 240,000 (1) 1.06 5 30,000 (1) 1.16 5 350,000 0.99 5 440,000 (1) 0.99 5 48,000 (1) 0.96 5 100,000 0.81 5 450,000 (1) 0.81 5 2,048,000 1.00 (1)
Schedule of stock options	Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2018 4,800,000 0.71 Expired/Cancelled (1,415,000 ) 0.66 Exercised (430,000 ) 0.15 Granted 2,048,000 1.00 Balance August 31, 2019 5,003,000 0.71 Expired/Cancelled (4,483,000 ) 0.98 Exercised (220,000 ) 0.14 Granted 4,848,000 0.39 Balance August 31, 2020 (Outstanding) 5,148,000 0.37 4.30 140,634 Balance August 31, 2020 (Exercisable) 4,262,000 0.34 4.29 136,853
Schedule of fair value of options granted	August 31 2020 August 31 2019 Expected volatility 95%- 96 % 100%- 144 % Risk-free interest rate 0.35%- 1.66 % 1.42%- 2.89 % Expected life 5 years 5 years Dividend yield 0 % 0 % Estimated fair value per option $ 0.31-$0.54 $ 0.60 - $1.07

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Aug. 31, 2020
Revenues [Abstract]
Schedule of revenue	August 31 2020 $ August 31 2019 $ Product sales 150,993 24,282 Licensing revenue (Note 11) 232,909 198,000 Freight revenue 641 328 384,543 222,610

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Aug. 31, 2020
Related Party Transactions [Abstract]
Schedule of related party transactions	Management, consulting and accounting services Cash $ % Non-Cash (2) $ % Aug 31 2020 Total $ Cash $ % Non-Cash (2) $ % Aug 31 2019 Total $ C.A.B Financial Services (1) 300,802 66 153,065 34 453,867 223,280 100 — — 223,280 M&E Services Ltd. (1) 121,664 46 143,886 54 265,550 112,377 100 — — 112,377 Docherty Management Limited (1) 242,521 47 275,614 53 518,135 195,740 100 — — 195,740 Company controlled by a director — — — — — 14,932 12 112,718 88 127,650 Directors 67,146 43 88,544 57 155,690 16,138 9 172,330 91 188,468 732,133 661,109 1,393,242 562,467 285,048 847,515 (1) (2)

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Aug. 31, 2020
Segment Reporting [Abstract]
Schedule of the profit or loss and total assets for each reportable segment	IP Licensing Consumer Products Corporate Consolidated Total External revenue 232,909 151,634 — 384,543 Cost of goods sold — (99,378 ) — (99,378 ) Operating expenses (1,601,595 ) (1,043,956 ) (1,724,227 ) (4,369,778 ) Segment loss (1,368,686 ) (991,700 ) (1,724,227 ) (4,084,613 ) Total assets 692,268 116,871 2,019,099 2,828,238
Schedule of capital asset by region	Capital Asset by Region Cost Net Balance Cost Net Balance Canada Canada Total Net Balance Balance Year Ended August 31, 2020 $ $ $ $ $ Leasehold Improvements — — 259,981 173,371 173,371 Computers — — 63,964 32,095 32,095 Furniture Fixtures Equipment 3,094 — 31,126 21,123 21,123 Lab Equipment 98,050 85,264 193,185 171,505 256,769 101,144 85,264 548,256 398,094 483,358 Capital Asset by Region Cost Net Balance Cost Net Balance Canada Canada Total Net Balance Balance Year Ended August 31, 2019 $ $ $ $ $ Leasehold Improvements — — 259,981 226,638 226,638 Computers — — 63,964 51,776 51,776 Furniture Fixtures Equipment 3,094 619 31,126 27,540 28,159 Lab Equipment 98,050 85,420 193,185 199,269 284,689 101,144 86,039 548,256 505,223 591,262

Commitments, Significant Cont_2

Commitments, Significant Contracts and Contingencies (Tables)	12 Months Ended
	Aug. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of management and service agreements	Party Monthly Commitment Expiry Date C.A.B Financial Services CAD $29,706 January 1, 2022 Docherty Management Ltd. CAD $25,609 January 1, 2022 M&E Services Ltd. CAD $13,997 June 1, 2021 Corporate Development CAD $1,500 Month to Month Office Management CAD $10,800 August 15, 2022 Research & Development CAD $3,854 Month to Month Office operating lease (1) CAD $4,823 November 15, 2023 Right of Use Assets - Operating Lease (1) Corporate office and R&D lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. In addition to minimum lease payments, the lease requires us to pay property taxes and operating costs which are subject to annual adjustments.
Schedule of information about operating lease	Right of use assets - operating leases: $ September 1, 2019 160,289 Amortization (33,369 ) Total lease assets 126,920 Liabilities: September 1, 2019 158,773 Lease payments (43,764 ) Interest accretion 10,423 Total lease liabilities 125,431 Operating lease cost as at August 31, 2020 $ 126,920 Operating cash flows for lease $ 43,764 Remaining lease term 3.1 Years Discount rate 7.25 %
Schedule of maturities of operating lease liabilities	2021 43,950 2022 44,599 2023 44,815 2024 7,469 Thereafter — Total lease payments 140,832 Less: imputed interest (15,401 ) Present value of operating lease liabilities 125,431 Less: current obligations under leases (36,038 ) Total 89,393

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Aug. 31, 2020
Prepaid Expense, Current [Abstract]
Schedule of prepaid expenses	August 31 2020 $ August 31 2019 $ Advertising & conferences 21,878 39,143 Legal fees 47,498 — Licence, filing fees, dues 8,541 — Office & insurance 78,792 29,784 Research & development 25,386 — 182,095 68,927

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Aug. 31, 2020
Marketable Securities [Abstract]
Schedule of marketable securities	Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2019 Common Stock 81,250 9,335 (12,124 ) Total 81,250 9,335 (26,973 ) 63,612 August Common Stock 56,250 9,997 (38,584 ) Total 56,250 9,997 (46,926 ) 19,321

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Aug. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of effective income tax rate reconciliation	August 31 2020 $ August 31 2019 $ Loss before taxes (3,987,018 ) (4,158,413 ) Expected income tax recovery (856,424 ) (883,841 ) Non-deductible items 200,573 8,544 Change in estimates 92,083 948 Effect of changes in foreign and long-term tax rates — — Change in valuation allowance 566,087 892,013 Total income taxes 2,319 17,664
Schedule of deferred taxes assets and liabilities	August 31 2020 $ August 31 2019 $ Non-capital losses 5,588,526 5,022,440 Marketable securities 2,300 2,300 Total unrecognized deferred tax assets 5,590,826 5,024,740
Schedule of carryforwards net operating loss	Year Amount Canada 2025 76,000 — 2026 508,000 — 2027 1,056,000 — 2028 720,000 — 2029 753,000 — 2030 552,000 — 2031 538,000 — 2032 252,000 — 2033 344,000 — 2034 3,257,000 — 2035 1,934,000 — 2036 1,150,000 — 2037 1,857,000 — 2038 — — 2039 — 242,000 2040 — 309,000 Indefinite 13,343,000 — 26,340,000 551,000 Total 26,891,000

Significant Accounting Polici_2

Significant Accounting Policies (Detail Textuals)	12 Months Ended
	Aug. 31, 2020USD ($)License	Aug. 31, 2019USD ($)License	Sep. 01, 2019USD ($)	Aug. 31, 2018USD ($)
Accounting Policies [Line Items]
Equipment, depreciation method	straight-line method
Patent, legal life	20 years
Cash	$ 1,293,749	$ 1,285,147		$ 1,727,184
Territory License Fee receivable	143,500	106,000
Bad debt expense	50,000	75,000
Sales tax receivable	87,933	161,418
Balance September 1, 2019	126,920	$ 0	$ 160,289
Balance September 1, 2019	$ 125,431		$ 158,773
Intellectual Property Territory License
Accounting Policies [Line Items]
Number of licensees | License	3	3

Basis of Consolidation (Detail

Basis of Consolidation (Detail Textuals)	Aug. 31, 2020
Lexaria Nicotine LLC
Equity interest percentage	83.333%
Altria Ventures Inc.
Equity interest percentage	16.667%

Accounts and Other Receivable_2

Accounts and Other Receivables (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Trade and deposits receivable	$ 82,492	$ 5,727
Territory License Fee receivable	143,500	106,000
Sales tax receivable	87,933	161,418
Accounts and other receivable	$ 313,925	$ 273,145

Inventory (Details)

Inventory (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 51,404	$ 45,068
Work in progress	15,705	0
Finished goods	49,762	82,328
Inventory	$ 116,871	$ 127,396

Inventory (Detail Textuals)

Inventory (Detail Textuals) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Inventory Disclosure [Abstract]
Inventory write-off	$ 8,240	$ 7,182

Intellectual Property (Details)

Intellectual Property (Details) - USD ($)		12 Months Ended
		Aug. 31, 2020	Aug. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Balance - beginning		$ 265,127	$ 146,538
Addition		33,645	122,982
Amortization	[1]	(6,772)	(4,393)
Balance - ending		$ 292,000	$ 265,127
[1]	The patents are amortized over their legal life of 20 years from the patent application’s filing date.

Intellectual Property (Detail T

Intellectual Property (Detail Textuals)	12 Months Ended
	Aug. 31, 2020
Alternative Health Products [Line Items]
Useful life	20 years

Property & Equipment (Details)

Property & Equipment (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Equipment	$ 649,400	$ 649,400
Less accumulated amortization	(166,043)	(58,137)
Balance - Ending	483,357	591,263
Period Amortization
Less accumulated amortization	(107,906)	(56,281)
Leasehold improvements
Equipment	259,981	259,981
Less accumulated amortization	(86,610)	(33,342)
Balance - Ending	173,371	226,639
Leasehold improvements | Period Amortization
Less accumulated amortization	(53,268)	(33,342)
Computers
Equipment	63,964	63,964
Less accumulated amortization	(31,869)	(12,187)
Balance - Ending	32,095	51,777
Computers | Period Amortization
Less accumulated amortization	(19,681)	(12,187)
Furniture fixtures equipment
Equipment	34,220	34,220
Less accumulated amortization	(13,097)	(6,062)
Balance - Ending	21,123	28,158
Furniture fixtures equipment | Period Amortization
Less accumulated amortization	(7,036)	(4,205)
Lab equipment
Equipment	291,235	291,235
Less accumulated amortization	(34,467)	(6,546)
Balance - Ending	256,768	284,689
Lab equipment | Period Amortization
Less accumulated amortization	$ (27,921)	$ (6,546)

Property & Equipment (Detail Te

Property & Equipment (Detail Textuals)	12 Months Ended
	Aug. 31, 2020USD ($)
Proceeds from Sale of Property, Plant, and Equipment [Abstract]
Amortization cost	$ 1,928

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Accounts Payable And Accrued Liabilities[Line Items]
Accounts payable and accrued liabilities	$ 86,920	$ 136,411
Accounts Payable
Accounts Payable And Accrued Liabilities[Line Items]
Trades payable	45,080	31,463
Sales tax payable	0	63,616
Accrued Liabilities
Accounts Payable And Accrued Liabilities[Line Items]
Trades payable	38,006	41,332
Corporate tax payable	$ 3,834	$ 0

Common Shares and Warrants (Det

Common Shares and Warrants (Details) - USD ($)		12 Months Ended
		Aug. 31, 2020		Aug. 31, 2019
Equity [Abstract]
Warrant exercise, number of shares	[1]			1,626,513
Warrant exercise, total value	[1]			$ 796,122
Option exercise, number of shares		220,000		430,000
Option exercise, total value		$ 30,030		$ 66,250
Private placement, number of Shares		10,689,956	[2]	947,150
Private placement, total Value		$ 2,859,914	[2]	$ 1,515,440
Per agreements, number of shares	[3]	347,222		250,000
Per agreements, total value	[3]	$ 100,000		$ 234,500
Total number of shares issued in exercise of options, private placement and per agreements		11,257,178		3,253,663
Total value of shares issued in exercise of options, private placement and per agreements		$ 2,989,944		$ 2,612,312
[1]	Includes 384,212 broker warrants exercised for gross proceeds of $191,742
[2]	Total fees of $221,889 were paid for total net receipt of $2,638,025.
[3]	The Company awarded the restricted common shares as required by consulting contracts.

Common Shares and Warrants (D_2

Common Shares and Warrants (Details 1) - $ / shares	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Common Shares And Warrants [Roll Forward]
Number of Warrants, Balance	2,825,325	3,286,274
Weighted Average Exercise Price, Balance	$ 1.38	$ 0.72
Number of Warrants, Cancelled/Expired	(750,000)	(17,498)
Weighted Average Exercise Price, Cancelled/Expired	$ 1.50	$ 0.59
Number of Warrants, Exercised		(1,626,513)
Weighted Average Exercise Price, Exercised		$ 0.49
Number of Warrants, Issued	12,072,829	1,183,062
Weighted Average Exercise Price, Issued	$ 0.42	$ 1.99
Number of Warrants, Balance	14,148,154	2,825,325
Weighted Average Exercise Price, Balance	$ 0.56	$ 1.38

Common Shares and Warrants (D_3

Common Shares and Warrants (Details 2) - $ / shares	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	5 years	5 years
Dividend yield	0.00%	0.00%
Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	95.00%	100.00%
Risk-free interest rate	0.35%	1.42%
Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	96.00%	144.00%
Risk-free interest rate	1.66%	2.89%
Warrant
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Dividend yield	0.00%	0.00%
Warrant | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	91.00%	1.00%
Risk-free interest rate	0.36%	2.31%
Expected life	2 years	1 day
Estimated fair value per warrant	$ 0.28
Warrant | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	94.00%	117.00%
Risk-free interest rate	2.87%	2.87%
Expected life	5 years	2 years
Estimated fair value per warrant	$ 0.54	$ 0.57

Common Shares and Warrants (D_4

Common Shares and Warrants (Details 3) - $ / shares	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019	Aug. 31, 2018
Number of Warrants	14,148,154	2,825,325	3,286,274
Weighted Average Remaining Contractual Life	3 years 7 months 2 days
Weighted Average Exercise Price	$ 0.56
# of Warrants 975,325
Number of Warrants	975,325
Weighted Average Remaining Contractual Life	2 months 1 day
Weighted Average Exercise Price	$ 2.25
# of Warrants 100,000
Number of Warrants	100,000
Weighted Average Remaining Contractual Life	8 months 19 days
Weighted Average Exercise Price	$ 0.96
# of Warrants 250,000
Number of Warrants	250,000
Weighted Average Remaining Contractual Life	8 months 23 days
Weighted Average Exercise Price	$ 1.55
# of Warrants 750,000
Number of Warrants	750,000
Weighted Average Remaining Contractual Life	1 year 1 month 9 days
Weighted Average Exercise Price	$ 0.14
# of Warrants 225,000
Number of Warrants	225,000
Weighted Average Remaining Contractual Life	2 years 2 months 4 days
Weighted Average Exercise Price	$ 0.80
# of Warrants 1,562,995
Number of Warrants	1,562,995
Weighted Average Remaining Contractual Life	1 year 2 months 12 days
Weighted Average Exercise Price	$ 0.80
# of Warrants 269,500
Number of Warrants	269,500
Weighted Average Remaining Contractual Life	1 year 2 months 26 days
Weighted Average Exercise Price	$ 0.80
# of Warrants 500,000
Number of Warrants	500,000
Weighted Average Remaining Contractual Life	4 years 6 months 14 days
Weighted Average Exercise Price	$ 0.30
# of Warrants 8,028,254
Number of Warrants	8,028,254
Weighted Average Remaining Contractual Life	4 years 8 months 4 days
Weighted Average Exercise Price	$ 0.35
# of Warrants 1,487,080
Number of Warrants	1,487,080
Weighted Average Remaining Contractual Life	4 years 8 months 12 days
Weighted Average Exercise Price	$ 0.35

Common Shares and Warrants (D_5

Common Shares and Warrants (Detail Textuals) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	May 31, 2020	May 31, 2020	Aug. 31, 2020	Aug. 31, 2019
Common Shares And Warrants [Line Items]
Number of units sold in private placement			1,823,745	947,150
Price per share of private placement units sold			$ 0.45	$ 1.60
Each Whole Compensation Warrant Exercisable Exercise Price				$ 2.25
Term of warrants			2 years
Fair value of warrants issued as share issue cost		$ 128,329	$ 1,850
Number of warrants issued	8,866,211
Exercise price of warrants			$ 0.56
Consulting Expense For Warrants Previously Granted To Consultant Upon Vesting				$ 51,448
Proceeds from Warrant Exercises	$ 2,039,229
Issue price of units issued	$ 0.23	$ 0.23
Amount of private placement fees paid			$ 221,889
Payment for net receipt amount of private placement			2,638,025
Legal and professional		$ 65,600	371,844	670,863
Warrants issued for services			168,833	52,817
Broker
Common Shares And Warrants [Line Items]
Fair value of warrants issued as share issue cost			$ 3,938	$ 6,484
Number Of Warrants Issued As Share Issue Cost			8,750
Number of warrants issued				107,737
Exercise price of warrants				$ 2.25
Warrants Issued				384,212
Fair Value Of Warrants Issued Pursuant To Consulting Agreements				$ 16,095
Proceeds from Warrant Exercises				$ 191,742
Number Of Broker Warrants Exercisable				28,175
Consulting agreements
Common Shares And Warrants [Line Items]
Fair value of warrants issued as share issue cost			$ 98,081	$ 52,817
Number of warrants issued			500,000	100,000
May 6, 2025
Common Shares And Warrants [Line Items]
Number of warrants issued	8,028,254
Exercise price of warrants	$ 0.35	$ 0.35
May 6, 2025 | Agent agreement
Common Shares And Warrants [Line Items]
Fair value of warrants issued as share issue cost	$ 151,623
May 6, 2025 | Broker
Common Shares And Warrants [Line Items]
Number of warrants issued	649,123
May 11, 2025
Common Shares And Warrants [Line Items]
Number of warrants issued	837,957
Exercise price of warrants	$ 0.35	$ 0.35
First anniversary
Common Shares And Warrants [Line Items]
Exercise price of warrants			$ 0.80
Second anniversary
Common Shares And Warrants [Line Items]
Exercise price of warrants			$ 1.20

Stock Options (Details)

Stock Options (Details) - $ / shares		12 Months Ended
		Aug. 31, 2020		Aug. 31, 2019
Quantity		4,848,000	[1]	2,048,000
Exercise price		$ 0.39		$ 1
Life (Years)		5 years
Stock Options 1
Quantity		1,000,000		390,000	[2]
Exercise price		$ 0.55		$ 1.27
Life (Years)		5 years		5 years
Stock Options 2
Quantity		60,000		240,000	[2]
Exercise price		$ 0.43		$ 1.06
Life (Years)		5 years		5 years
Stock Options 3
Quantity		550,000		30,000	[2]
Exercise price		$ 0.47		$ 1.16
Life (Years)		5 years		5 years
Stock Options 4
Quantity		2,538,000		350,000
Exercise price		$ 0.32		$ 0.99
Life (Years)		5 years		5 years
Stock Options 5
Quantity		700,000		440,000	[2]
Exercise price		$ 0.34		$ 0.99
Life (Years)		5 years		5 years
Stock Options 6
Quantity	[2]			48,000
Exercise price				$ 0.96
Life (Years)				5 years
Stock Options 7
Quantity				100,000
Exercise price				$ 0.81
Life (Years)				5 years
Stock Options 8
Quantity	[2]			450,000
Exercise price				$ 0.81
Life (Years)				5 years
[1]	3,962,000 have vested as at August 31, 2020, and 886,000 remain subject to vesting provisions.
[2]	Options granted vest over a period of three years

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Options
Balance, Outstanding	5,003,000	4,800,000
Expired/Cancelled	(4,483,000)	(1,415,000)
Exercised	(220,000)	(430,000)
Granted	4,848,000	2,048,000
Balance, Outstanding	5,148,000	5,003,000
Balance, Exercisable	4,262,000
Weighted Average Exercise Price
Balance, Outstanding	$ 0.71	$ 0.71
Expired/Cancelled	0.98	0.66
Exercise Price	0.14	0.15
Granted	0.39	1
Balance, Outstanding	0.37	$ 0.71
Balance, Exercisable	$ 0.34
Weighted Average Remaining Contractual Term, Outstanding (Years)	4 years 3 months 18 days
Weighted Average Remaining Contractual Term, Exercisable (Years)	4 years 3 months 14 days
Aggregate Intrinsic Value, Outstanding	$ 140,634
Aggregate Intrinsic Value, Exercisable	$ 136,853

Stock Options (Details 2)

Stock Options (Details 2) - $ / shares	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years	5 years
Dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	95.00%	100.00%
Risk-free interest rate	0.35%	1.42%
Estimated fair value per option	$ 0.31	$ 0.60
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	96.00%	144.00%
Risk-free interest rate	1.66%	2.89%
Estimated fair value per option	$ 0.54	$ 1.07

Stock Options (Detail Textuals)

Stock Options (Detail Textuals) - $ / shares	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.39	$ 1
Term of expiration	5 years
2019 Equity Incentive Plan | Directors Officers Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant	7,838,713
2014 Stock Option Plan | Directors Officers Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant	2,107,500
Stock Options 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.55	1.27
Stock Options 1 | On grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options vested on grant	3,962,000
Stock Options 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.43	$ 1.06
Stock Options 2 | Annually thereafter until fully vested
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options expected to vest annually	886,000

Revenues (Details)

Revenues (Details) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Revenue [Line Items]
Revenue	$ 384,543	$ 222,610
Product sales
Revenue [Line Items]
Revenue	150,993	24,282
Licensing revenue
Revenue [Line Items]
Revenue	232,909	198,000
Freight revenue
Revenue [Line Items]
Revenue	$ 641	$ 328

Revenues (Detail Textuals)

Revenues (Detail Textuals) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 384,543	$ 222,610
Deferred revenue	44,255
Licensing revenue
Disaggregation of Revenue [Line Items]
Revenue	232,909	198,000
Product sales
Disaggregation of Revenue [Line Items]
Revenue	150,993	$ 24,282
Revenue from intermediate product for use by five customers	$ 121,906

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)		12 Months Ended
		Aug. 31, 2020		Aug. 31, 2019
Related Party Transaction [Line Items]
Cash		$ 732,133		$ 562,467
Non-Cash		661,109	[1]	285,048
Management, consulting and accounting services		1,393,242		847,515
C.A.B Financial Services Ltd. ("CAB")
Related Party Transaction [Line Items]
Cash	[2]	$ 300,802		$ 223,280
Percentage of cash	[2]	66.00%		100.00%
Non-Cash	[1],[2]	$ 153,065		$ 0
Percentage of non cash	[2]	34.00%		0.00%
Management, consulting and accounting services	[2]	$ 453,867		$ 223,280
M&E Services Ltd. ("M&E")
Related Party Transaction [Line Items]
Cash	[2]	$ 121,664		$ 112,377
Percentage of cash	[2]	46.00%		100.00%
Non-Cash	[1],[2]	$ 143,886		$ 0
Percentage of non cash	[2]	54.00%		0.00%
Management, consulting and accounting services		$ 265,550	[2]	$ 112,377
Docherty Management Limited ("Docherty Management")
Related Party Transaction [Line Items]
Cash	[2]	$ 242,521		$ 195,740
Percentage of cash	[2]	47.00%		100.00%
Non-Cash	[1],[2]	$ 275,614		$ 0
Percentage of non cash	[2]	53.00%		0.00%
Management, consulting and accounting services	[2]	$ 518,135		$ 195,740
Company controlled by a director
Related Party Transaction [Line Items]
Cash		$ 0		$ 14,932
Percentage of cash		0.00%		12.00%
Non-Cash	[1]	$ 0		$ 112,718
Percentage of non cash		0.00%		88.00%
Management, consulting and accounting services		$ 0		$ 127,650
Directors
Related Party Transaction [Line Items]
Cash		$ 67,146		$ 16,138
Percentage of cash		43.00%		9.00%
Non-Cash	[1]	$ 88,544		$ 172,330
Percentage of non cash		57.00%		91.00%
Management, consulting and accounting services		$ 155,690		$ 188,468
[1]	Stock Based Compensation (SBC) and Share Awards are included in the total value of the grants and awards included in expenses. In the year ended August 31, 2020 the Company granted $572,565 of option awards to officers and $88,544 awards to Directors included in Consulting expense replacing cancelled options (Note 13).
[2]	C.A.B. Financial Services is owned by the CEO of the Company, M&E Services Ltd. is owned by the CFO of the Company, and Docherty Management Limited is owned by the President of the Company.

Related Party Transactions (D_2

Related Party Transactions (Detail Textuals) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Related Party Transaction [Line Items]
Due to related parties	$ 58,704	$ 48,096
Officers
Related Party Transaction [Line Items]
Value of option awards granted	572,565
Directors
Related Party Transaction [Line Items]
Value of option awards granted	$ 88,544

Segment Information (Details)

Segment Information (Details) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
External revenue	$ 384,543	$ 222,610
Cost of goods sold	(99,378)	(22,893)
Operating expenses	(4,369,778)	(4,358,130)
Segment loss	(4,084,613)	(4,158,413)
Total assets	2,828,238	$ 2,675,219
IP Licensing
External revenue	232,909
Cost of goods sold	0
Operating expenses	(1,601,595)
Segment loss	(1,368,686)
Total assets	692,268
Consumer Products
External revenue	151,634
Cost of goods sold	(99,378)
Operating expenses	(1,043,956)
Segment loss	(991,700)
Total assets	116,871
Corporate
External revenue	0
Cost of goods sold	0
Operating expenses	(1,724,227)
Segment loss	(1,724,227)
Total assets	$ 2,019,099

Segment Information (Details 1)

Segment Information (Details 1) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Segment Reporting Information [Line Items]
Net Balance	$ 483,357	$ 591,263
US
Segment Reporting Information [Line Items]
Cost	101,144	101,144
Net Balance	85,264	86,039
Canada
Segment Reporting Information [Line Items]
Cost	548,256	548,256
Net Balance	398,094	505,223
Leasehold improvements
Segment Reporting Information [Line Items]
Net Balance	173,371	226,639
Leasehold improvements | US
Segment Reporting Information [Line Items]
Cost	0	0
Net Balance	0	0
Leasehold improvements | Canada
Segment Reporting Information [Line Items]
Cost	259,981	259,981
Net Balance	173,371	226,638
Computers
Segment Reporting Information [Line Items]
Net Balance	32,095	51,777
Computers | US
Segment Reporting Information [Line Items]
Cost	0	0
Net Balance	0	0
Computers | Canada
Segment Reporting Information [Line Items]
Cost	63,964	63,964
Net Balance	32,095	51,776
Furniture fixtures equipment
Segment Reporting Information [Line Items]
Net Balance	21,123	28,158
Furniture fixtures equipment | US
Segment Reporting Information [Line Items]
Cost	3,094	3,094
Net Balance	0	619
Furniture fixtures equipment | Canada
Segment Reporting Information [Line Items]
Cost	31,126	31,126
Net Balance	21,123	27,540
Lab equipment
Segment Reporting Information [Line Items]
Net Balance	256,768	284,689
Lab equipment | US
Segment Reporting Information [Line Items]
Cost	98,050	98,050
Net Balance	85,264	85,420
Lab equipment | Canada
Segment Reporting Information [Line Items]
Cost	193,185	193,185
Net Balance	$ 171,505	$ 199,269

Segment Information (Detail Tex

Segment Information (Detail Textuals)	12 Months Ended
	Aug. 31, 2020Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Commitments, Significant Cont_3

Commitments, Significant Contracts and Contingencies (Details)	12 Months Ended
	Aug. 31, 2020CAD ($)
C.A.B Financial Services
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 29,706
Expiry Date	January 1, 2022
Docherty Management Ltd.
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 25,609
Expiry Date	January 1, 2022
M&E Services Ltd.
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 13,997
Expiry Date	June 1, 2021
Corporate development
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 1,500
Expiry Date	Month to Month
Office management
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 10,800
Expiry Date	August 15, 2022
Research & development
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 3,854
Expiry Date	Month to Month
Office operating lease
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 4,823	[1]
Expiry Date	November 15, 2023	[1]
[1]	Corporate office and R&D lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. In addition to minimum lease payments, the lease requires us to pay property taxes and operating costs which are subject to annual adjustments.

Commitments, Significant Cont_4

Commitments, Significant Contracts and Contingencies (Details 1) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2020	Sep. 01, 2019
Right Of Use Asset [Abstract]
Balance September 1, 2019	$ 0	$ 126,920	$ 160,289
Total lease assets	0
Amortization	(33,369)
Total lease assets	126,920
Operating Lease Liabilities [Abstract]
Balance September 1, 2019	125,431	$ 125,431	$ 158,773
Lease payments	(43,764)
Interest accretion	10,423
Total lease liabilities	125,431
Operating lease cost as at August 31, 2020	126,920
Operating cash flows for lease	$ 43,764
Remaining lease term		3 years 1 month 6 days
Discount rate		7.25%

Commitments, Significant Cont_5

Commitments, Significant Contracts and Contingencies (Details 2) - USD ($)	Aug. 31, 2020	Sep. 01, 2019	Aug. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
2021	$ 43,950
2022	44,599
2023	44,815
2024	7,469
Thereafter	0
Total lease payments	140,832
Less: imputed interest	(15,401)
Balance September 1, 2019	125,431	$ 158,773
Less: current obligations under leases	(36,038)		$ 0
Total	$ 89,393

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Prepaid Expense, Current [Abstract]
Advertising & Conferences	$ 21,878	$ 39,143
Legal fees	47,498	0
Licence, filing fees, dues	8,541	0
Office & Insurance	78,792	29,784
Research & Development	25,386	0
Prepaid expenses	$ 182,095	$ 68,927

Marketable Securities (Details)

Marketable Securities (Details) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Marketable Securities [Line Items]
Cost Basis	$ 56,250	$ 81,250
Unrealized Gains	9,997	9,335
Unrealized Losses	(46,926)	(26,973)
Total	19,321	64,214
Common stock
Marketable Securities [Line Items]
Cost Basis	56,250	81,250
Unrealized Gains	9,997	9,335
Unrealized Losses	$ (38,584)	$ (12,124)

Marketable Securities (Detail T

Marketable Securities (Detail Textuals)	12 Months Ended
	Aug. 31, 2020USD ($)
Marketable Securities [Abstract]
Marketable securities realised loss received from licensee in lieu of cash	$ 18,198
Proceeds from sale of Marketable securities received from licensee in lieu of cash	$ 6,802

Income Tax (Details)

Income Tax (Details) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Income Tax Disclosure [Abstract]
Loss before taxes	$ (3,987,018)	$ (4,158,413)
Expected income tax recovery	(856,424)	(883,841)
Non-deductible items	200,573	8,544
Change in estimates	92,083	948
Effect of changes in foreign and long-term tax rates	0	0
Change in valuation allowance	566,087	892,013
Total income taxes	$ 2,319	$ 17,664

Income Tax (Details 1)

Income Tax (Details 1) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Income Tax Disclosure [Abstract]
Non-capital losses	$ 5,588,526	$ 5,022,440
Marketable securities	2,300	2,300
Total unrecognized deferred tax assets	$ 5,590,826	$ 5,024,740

Income Tax (Details 2)

Income Tax (Details 2)	Aug. 31, 2020USD ($)
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 26,891,000
Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	26,340,000
Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	551,000
2025 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	76,000
2025 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2026 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	508,000
2026 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2027 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,056,000
2027 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2028 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	720,000
2028 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2029 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	753,000
2029 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2030 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	552,000
2030 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2031 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	538,000
2031 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2032 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	252,000
2032 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2033 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	344,000
2033 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2034 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	3,257,000
2034 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2035 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,934,000
2035 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2036 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,150,000
2036 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2037 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,857,000
2037 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2038 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2038 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2039 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2039 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	242,000
2040 | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	0
2040 | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	309,000
Indefinite | Amount
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	13,343,000
Indefinite | Canada
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 0

Income Tax (Detail Textuals)

Income Tax (Detail Textuals)	Aug. 31, 2020USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 26,891,000